PharmAbcine announced on August 31 that it had signed a contract manufacturing organization(CMO) agreement with Binex. With the new contract, Binex will produce Olinvacimab (TTAC-0001), PharmAbcine's leading antibody therapeutics pipeline in oncology, using the new 5,000L production line while it was previously produced in the 1,000L production line. This contract will allow Binex to start the operation of its new 5,000L production line designed for large-scale commercial production. As for PharmAbcine, this agreement will accommodate more timely and less costly delivery of Olinvacimab for its rapidly expanding list of both clinical and non-clinical studies. The list of studies includes, among others, the global clinical trial for Avastin refractory rGBM(recurrent glioblastoma multiforme) patients, the global combination trial with pembrolizumab for mTNBC(metastatic triple negative breast cancer), the research collaboration with SLBio in China for non-small cell lung cancer therapeutics, multiple investigator-initiated studies planned for solid tumors, etc.
BINEX.CO.LTD is a Korea-based company mainly engaged in the manufacturing and distribution of pharmaceuticals. The Companyâs products include digestive system agents, circulatory system agents, ulcer agents, antacids, anti-inflammatory agents, analgesics, gastrointestinal (GI) tract regulators and antispasmodics, antiemetic drugs, antihistamines, laxatives, antihypertensive and urinary agents, antibacterial and antibiotic agents, cough and cold remedies, anti-diabetic medicines, ophthalmic solutions, vitamins, nutrients, as well as ointment, creams and others. It also manufactures bio medicines and raw materials. The Company distributes its products within domestic market and to overseas markets.
BINEX CO., LTD. 
